Medartis shareholders endorse Board proposals with strong support at AGM 2025

MEDIA RELEASE

Medartis shareholders endorse Board proposals with strong support at AGM 2025

• − Strong participation with 82.8% of total share capital validly represented

• − All proposals by the Board of Directors were approved with a large majority

• − All eight board members were re-elected for another term of office

Basel, 25 April 2025: The shareholders of Medartis Holding AG (SIX: MED) today approved all the substantive proposals of the Board of Directors with significant majority exceeding 94.0%. All members of the Board of Directors were standing for re-election and received resounding endorsement, with each securing more than 96.6% support from represented votes. The Annual Gen The shareholders of Medartis Holding AG (SIX: MED) today approved all the substantive proposals of the Board of Directors with substantial majority exceeding 94.0%. eral Meeting took place at Medartis headquarters in Basel, continuing the tradition of direct shareholder engagement.

The Annual General Meeting (AGM) saw significant shareholder participation, with 11,252,628 shares directly or indirectly represented, constituting 82.8% of the total share capital. Shareholders granted discharge to the Board members for their governance during the 2024 term. The shareholders approved through separate votes the proposed maximum total remuneration for both the Board of Directors and the Executive Management Board, including fixed and variable components. The 2024 management report and annual financial statements received nearly unanimous approval (99.99%), while the remuneration report was approved by 94.1% in a consultative vote. Additionally, the sustainability report gained strong endorsement (95.9%) of represented shares, confirming Medartis' commitment to transparent ESG practices.

Chairman Marco Gadola will continue to lead the Board with all Board members re-elected for a one-year term extending to the AGM 2026. The assembly also confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee (HRCC), ensuring continuity in the oversight of the company's human capital strategy.

As of today's Annual General Meeting, the Medartis Board of Directors consists of the following members:

HRCC = Human Resources and Compensation Committee | SIC = Strategy and Innovation Committee | FAC = Finance and Audit Committee

In accordance with the proposal of the Board of Directors, the shareholders confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors. For a detailed listing of all resolutions at the 2025 Annual General Meeting,please visit this link. The next AGM is scheduled to take place on 23 April 2026. Medartis will report its H1 2025 results on 19 August 2025.

About Medartis

Founded in 1997 and headquartered in Basel, Switzerland, Medartis (SIX Swiss exchange: MED / ISIN CH0386200239) is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs approx. 950 individuals across its 13 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best-in-class service. For more information, please visitwww.medartis.com.

Your contact:

Corporate Communications

Investor contact:investor.relations@medartis.com Media contact:corporate.communication@medartis.com Phone +41 61 633 37 36

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained herein or of the views given or implied.

2